Clinical Trial Update: Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

View source ↗

Summary

Expanded Access Program update for Nintedanib in idiopathic pulmonary fibrosis, noting that the therapy is approved for marketing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• Nintedanib (nintedanib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Idiopathic Pulmonary Fibrosis | Status: APPROVED_FOR_MARKETING